Supplementary protection
LT - 2,4,6-Trifluor-N-[6-(1-metil-piperidin-4-karbonil)-piridin-2-il]-benzamidas migrenos gydymui, skiriant peroraliai arba intraveniniu būdu
EN - 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE FOR THE TREATMENT OF MIGRAINE VIA THE ORAL OR INTRAVENOUS ROUTE
SPC
| (11) |
Number of the document |
C 2413933 |
| (68) |
Number of the document |
2413933
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2023 502 |
| (22) |
Date of filing the application |
2023-01-06 |
| (41) |
Date of publication of the application |
2023-01-25 |
|
Date of publication of SPC |
2025-03-10 |
| (24) |
Date of coming into effect of SPC |
2030-04-03 |
Applicant
| (71) |
Colucid Pharmaceuticals, Inc.,
2530 Meridian Parkway, Suite 300, Durham, NC 27713,
US
|
Grantee
| (73) |
Colucid Pharmaceuticals, Inc.,
2530 Meridian Parkway, Suite 300, Durham, NC 27713,
US
|
Attorney or representative
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/21/1587, 2022-08-17
|
Calculated date of expiry of the SPC
| (94) |
2035-04-02 |
Name of the product protected by the basic patent
| (95) |
Lasmiditanas arba jo farmaciniu požiūriu priimtina druska |
